A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and ...
Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...
Brukinsa demonstrated lower treatment switching rates in CLL/SLL patients compared to Calquence and Imbruvica in both first-line and second-line settings. The study involved 2,816 first-line and 1,253 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results